BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 29305520)

  • 21. Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions.
    Hajaj E; Zisman E; Tzaban S; Merims S; Cohen J; Klein S; Frankenburg S; Sade-Feldman M; Tabach Y; Yizhak K; Navon A; Stepensky P; Hacohen N; Peretz T; Veillette A; Karni R; Eisenberg G; Lotem M
    Cancer Immunol Res; 2021 Jun; 9(6):637-650. PubMed ID: 33762352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
    Hajaj E; Eisenberg G; Klein S; Frankenburg S; Merims S; Ben David I; Eisenhaure T; Henrickson SE; Villani AC; Hacohen N; Abudi N; Abramovich R; Cohen JE; Peretz T; Veillette A; Lotem M
    Elife; 2020 Mar; 9():. PubMed ID: 32122464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLAMF6 as a Regulator of Exhausted CD8
    Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
    Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SLAMF6 clustering is required to augment T cell activation.
    Dragovich MA; Adam K; Strazza M; Tocheva AS; Peled M; Mor A
    PLoS One; 2019; 14(6):e0218109. PubMed ID: 31199820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble SLAMF6 Receptor Induces Strong CD8
    Eisenberg G; Engelstein R; Geiger-Maor A; Hajaj E; Merims S; Frankenburg S; Uzana R; Rutenberg A; Machlenkin A; Frei G; Peretz T; Lotem M
    Cancer Immunol Res; 2018 Feb; 6(2):127-138. PubMed ID: 29305520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLAMF6 in health and disease: Implications for therapeutic targeting.
    Yigit B; Wang N; Herzog RW; Terhorst C
    Clin Immunol; 2019 Jul; 204():3-13. PubMed ID: 30366106
    [No Abstract]   [Full Text] [Related]  

  • 29. Preclinical studies, experimental therapeutics, and clinical management of advanced melanoma.
    Kirkwood JM
    Curr Opin Oncol; 1992 Apr; 4(2):368-79. PubMed ID: 1591310
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.